Clinical Trial Update: Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pravastatin to delay recurrence of hepatocellular carcinoma in patients with liver cirrhosis was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cirrhosis

Drugs mentioned

• Pravastatin (pravastatin)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Hepatocellular Carcinoma, Liver Cirrhoses | Phase 2 | Status: TERMINATED | Results posted: 2021-01-22